{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T14:37:38Z","timestamp":1795185458337,"version":"4.10.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Helsinki University Hospital research funds","award":["TYH2020302"],"award-info":[{"award-number":["TYH2020302"]}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["WBS4708719"],"award-info":[{"award-number":["WBS4708719"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"DOI":"10.1038\/s44276-025-00125-6","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:58:47Z","timestamp":1739368727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3467-7194","authenticated-orcid":false,"given":"Karoliina","family":"Aro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Loukovaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Pasanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"125_CR1","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov\u00e1k Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N. Engl J Med [Internet]. 2023;388:2145\u201358. https:\/\/pubmed.ncbi.nlm.nih.gov\/36972026\/.","journal-title":"N. Engl J Med [Internet]"},{"key":"125_CR2","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med [Internet]. 2023;388:2159\u201370. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2302312.","journal-title":"N Engl J Med [Internet]"},{"key":"125_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med [Internet]. 2022;386:437\u201348. https:\/\/pubmed.ncbi.nlm.nih.gov\/35045221\/.","journal-title":"N Engl J Med [Internet]"},{"key":"125_CR4","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","volume":"26","author":"AN Fader","year":"2020","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin\u2013paclitaxel compared with carboplatin\u2013paclitaxel\u2013trastuzumab in advanced (stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26:3928\u201335.","journal-title":"Clin Cancer Res"},{"key":"125_CR5","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol [Internet]. 2018;36:2044\u201351. https:\/\/pubmed.ncbi.nlm.nih.gov\/29584549\/.","journal-title":"J Clin Oncol [Internet]"},{"key":"125_CR6","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol [Internet]. 2024;42:47\u201358. https:\/\/pubmed.ncbi.nlm.nih.gov\/37870536\/.","DOI":"10.1200\/JCO.23.02005"},{"key":"125_CR7","doi-asserted-by":"publisher","unstructured":"Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: post hoc analysis of DESTINY-PanTumor02. Adv Ther. 2024;11:4125\u201339. https:\/\/doi.org\/10.1007\/12325-02402975-x.","DOI":"10.1007\/12325-02402975-x"},{"key":"125_CR8","doi-asserted-by":"crossref","unstructured":"Bai X, Sun P, Wang X, Long C, Liao S, Dang S, et al. Structure and dynamics of the EGFR\/HER2 heterodimer. Cell Discov [Internet]. 2023 Dec [cited 2024 May 29];9. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36781849\/.","DOI":"10.1038\/s41421-023-00523-5"},{"key":"125_CR9","doi-asserted-by":"crossref","unstructured":"Galogre M, Rodin D, Pyatnitskiy M, Mackelprang M, Koman I. A review of HER2 overexpression and somatic mutations in cancers. Crit Rev Oncol Hematol [Internet]. 2023 Jun [cited 2024 May 29];186. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37062337\/.","DOI":"10.1016\/j.critrevonc.2023.103997"},{"key":"125_CR10","doi-asserted-by":"crossref","unstructured":"Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol [Internet]. 2001 [cited 2024 May 16];12. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11521719\/.","DOI":"10.1093\/annonc\/12.suppl_1.S3"},{"key":"125_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev [Internet]. 2015;34:157\u201364. https:\/\/pubmed.ncbi.nlm.nih.gov\/25712293\/.","journal-title":"Cancer Metastasis Rev [Internet]"},{"key":"125_CR12","unstructured":"2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"125_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ygyno.2022.10.024","volume":"168","author":"CS Walsh","year":"2023","unstructured":"Walsh CS, Hacker KE, Secord AA, DeLair DF, McCourt C, Urban R. Molecular testing for endometrial cancer: an SGO clinical practice statement. Gynecol Oncol [Internet]. 2023;168:48\u201355. https:\/\/pubmed.ncbi.nlm.nih.gov\/36399812\/.","journal-title":"Gynecol Oncol [Internet]"},{"key":"125_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","volume":"159","author":"BK Erickson","year":"2020","unstructured":"Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, et al. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study. Gynecol Oncol [Internet]. 2020;159:17\u201322. https:\/\/pubmed.ncbi.nlm.nih.gov\/32709539\/.","journal-title":"Gynecol Oncol [Internet]"},{"key":"125_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","volume":"33","author":"D Rottmann","year":"2020","unstructured":"Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, et al. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Mod Pathol [Internet]. 2020;33:118\u201327. https:\/\/pubmed.ncbi.nlm.nih.gov\/31477811\/.","journal-title":"Mod Pathol [Internet]"},{"key":"125_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","volume":"108","author":"TA Grushko","year":"2008","unstructured":"Grushko TA, Filiaci VL, Mundt AJ, Ridderstr\u00e5le K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol [Internet]. 2008;108:3\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/17945336\/.","journal-title":"Gynecol Oncol [Internet]"},{"key":"125_CR17","doi-asserted-by":"publisher","unstructured":"Van Dijk D, Vermij L, Le\u00f3n-Castillo A, Powell M, Jobsen J, Leary A, et al. Clinical and molecular characteristics of high-risk, recurrent, or metastatic endometrial cancer that is human epidermal growth factor receptor 2-low. J Clin Oncol. 2025;43:443\u201352. https:\/\/doi.org\/10.1200\/JCO.23.2768.","DOI":"10.1200\/JCO.23.2768"},{"key":"125_CR18","doi-asserted-by":"publisher","unstructured":"Krakstad C, Berg HF, Lindemann K, Halle MK. Frequency of ERBB2-low expression in endometrial cancer. JAMA Oncol. 2024;10:1587\u201388. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3660.","DOI":"10.1001\/jamaoncol.2024.3660"},{"key":"125_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","volume":"105","author":"S Pecorelli","year":"2009","unstructured":"Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet [Internet]. 2009;105:103\u20134. https:\/\/pubmed.ncbi.nlm.nih.gov\/19367689\/.","journal-title":"Int J Gynaecol Obstet [Internet]"},{"key":"125_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","volume":"31","author":"N Concin","year":"2021","unstructured":"Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer [Internet]. 2021;31:12\u201339. https:\/\/pubmed.ncbi.nlm.nih.gov\/33397713\/.","journal-title":"Int J Gynecol Cancer [Internet]"},{"key":"125_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/bjc.2015.190","volume":"113","author":"A Talhouk","year":"2015","unstructured":"Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer [Internet]. 2015;113:299\u2013310. https:\/\/pubmed.ncbi.nlm.nih.gov\/26172027\/.","journal-title":"Br J Cancer [Internet]"},{"key":"125_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","volume":"159","author":"C Karakas","year":"2023","unstructured":"Karakas C, Tyburski H, Turner BM, Wang X, Schiffhauer LM, Katerji H, et al. Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low\u2013expressing breast cancer cohort. Am J Clin Pathol. 2023;159:484\u201391.","journal-title":"Am J Clin Pathol"},{"key":"125_CR23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","volume":"26","author":"N Buza","year":"2013","unstructured":"Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol. 2013;26:1605\u201312.","journal-title":"Mod Pathol"},{"key":"125_CR24","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","volume":"35","author":"DS Ross","year":"2022","unstructured":"Ross DS, Devereaux KA, Jin C, Te Lin DY, Zhang Y, Marra A, et al. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas. Mod Pathol [Internet]. 2022;35:962\u201371. http:\/\/www.modernpathology.org\/article\/S0893395222000862\/fulltext.","journal-title":"Mod Pathol [Internet]"},{"key":"125_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med [Internet]. 2022;387:9\u201320. https:\/\/pubmed.ncbi.nlm.nih.gov\/35665782\/.","journal-title":"N Engl J Med [Internet]"},{"key":"125_CR26","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.22.02558","volume":"41","author":"T Nishikawa","year":"2023","unstructured":"Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial. J Clin Oncol [Internet]. 2023;41:2789\u201399.","journal-title":"J Clin Oncol [Internet]"},{"key":"125_CR27","doi-asserted-by":"crossref","unstructured":"Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest [Internet]. 2000;80:1943\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/11140706\/.","DOI":"10.1038\/labinvest.3780204"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00125-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:58:52Z","timestamp":1739368732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00125-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00125-6","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Helsinki University Hospital institutional review board and the National Supervisory Authority for Welfare and Health. Participants in the prospective study gave written informed consent in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"8"}}